NCT02744053Active, not recruitingEarly phase 1
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
This early phase I trial studies how well dynamic contrast enhanced molecular resonance imaging (DCE-MRI) and technetium-Tc99m sestamibi molecular breast imaging (MBI) work in assessing tumor response to chemotherapy in patients with triple negative breast cancer (TNBC) who are undergoing chemotherapy. Investigational imaging scans such as MBI and DCE-MRI may help researchers predict which patients may respond to treatment.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 96 (actual)
- First submitted
- 5 Apr 2016
- Start date
- 7 Nov 2016
- Primary completion date
- 30 Apr 2028
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT02744053
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 96
- From 7 Nov 2016 to the primary completion date, 30 Apr 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has known allergy to Tc99m sestamibi
Other
- Is pregnant (confirmed by the patient as imaging clinic standard of care) or nursing mother
- Has lesions involving chest wall
- Has known contraindications to MRI
- Has contraindication to MRI contrast
Who the study is looking for
- The patient has proven TNBC, defined by standard pathologic assays as negative for estrogen receptor (ER) and progesterone receptor (PR) (\< 10% tumor staining) and negative for human epidermal growth factor 2 (HER2) (immunohistochemistry \[IHC\] score \< 3, gene copy number not amplified)
- TNBC patients who are previously untreated and enrolled in the prospective Institutional Review Board (IRB) approved clinical trial: 2014-0185
- Patients who are able to understand and give consent to participating in the study
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| M D Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Memorial Hermann Memorial City Medical Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| MD Anderson in Katy Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| MD Anderson League City Coordinator of this site? Confirm its status | Nassau Bay | United States | Unknown status |
| MD Anderson in Sugar Land Coordinator of this site? Confirm its status | Sugar Land | United States | Unknown status |
| MD Anderson in The Woodlands Coordinator of this site? Confirm its status | The Woodlands | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.